Piper Sandler raised the firm’s price target on Quest Diagnostics (DGX) to $200 from $190 following quarterly results. The firm keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $205 from $195 at Truist
- Quest Diagnostics price target raised to $207 from $191 at Morgan Stanley
- Quest Diagnostics price target raised to $195 from $190 at Barclays
- Quest Diagnostics Reports Strong Q3 2025 Results
- Quest Diagnostics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating